TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
This study suggests that PwHA receiving emicizumab prophylaxis can participate in a wide range of physical activities with minimal bleeding risk, which supports their access to the health benefits of exercise. Emicizumab remains well tolerated.
Authors
- Keiji Nogami (ORCID: https://orcid.org/0000-0002-2415-2194)
- N. Hattori
- Teruhisa Fujii (ORCID: https://orcid.org/0000-0002-6959-6346)
- Tomomi Shimura
- Chiai Nagae
- Azusa Nagao (ORCID: https://orcid.org/0000-0002-1126-1498)
- Kagehiro Amano (ORCID: https://orcid.org/0000-0003-3186-7267)
- Masanori Nojima (ORCID: https://orcid.org/0000-0002-8788-2522)
- Nobuaki Suzuki (ORCID: https://orcid.org/0000-0003-2250-7964)
- Yoshimasa Sugao
- Akihiro Sawada
- Mika Kawano
Institutions
- Tokyo Medical University (JP)
- Tokyo University of Science (JP)
- St. Marianna University School of Medicine (JP)
- Nagoya University Hospital (JP)
- Ogikubo Hospital (JP)
- Hiroshima University Hospital (JP)
- Nara Medical University (JP)
- Hyogo University (JP)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1111/hae.70070
- Citations
- 8
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 14.16
Funders
- Chugai Pharmaceutical